1. Home
  2. CHRS vs IDE Comparison

CHRS vs IDE Comparison

Compare CHRS & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • IDE
  • Stock Information
  • Founded
  • CHRS 2010
  • IDE 2010
  • Country
  • CHRS United States
  • IDE United States
  • Employees
  • CHRS N/A
  • IDE N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • IDE Finance/Investors Services
  • Sector
  • CHRS Health Care
  • IDE Finance
  • Exchange
  • CHRS Nasdaq
  • IDE Nasdaq
  • Market Cap
  • CHRS 84.2M
  • IDE 173.1M
  • IPO Year
  • CHRS 2014
  • IDE N/A
  • Fundamental
  • Price
  • CHRS $0.82
  • IDE $11.71
  • Analyst Decision
  • CHRS Buy
  • IDE
  • Analyst Count
  • CHRS 3
  • IDE 0
  • Target Price
  • CHRS $4.68
  • IDE N/A
  • AVG Volume (30 Days)
  • CHRS 1.3M
  • IDE 33.5K
  • Earning Date
  • CHRS 08-07-2025
  • IDE 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • IDE 8.83%
  • EPS Growth
  • CHRS N/A
  • IDE N/A
  • EPS
  • CHRS N/A
  • IDE N/A
  • Revenue
  • CHRS $272,251,000.00
  • IDE N/A
  • Revenue This Year
  • CHRS N/A
  • IDE N/A
  • Revenue Next Year
  • CHRS $106.56
  • IDE N/A
  • P/E Ratio
  • CHRS $1.90
  • IDE N/A
  • Revenue Growth
  • CHRS 19.87
  • IDE N/A
  • 52 Week Low
  • CHRS $0.66
  • IDE $8.61
  • 52 Week High
  • CHRS $2.43
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 53.65
  • IDE 72.19
  • Support Level
  • CHRS $0.72
  • IDE $11.30
  • Resistance Level
  • CHRS $0.77
  • IDE $11.48
  • Average True Range (ATR)
  • CHRS 0.04
  • IDE 0.08
  • MACD
  • CHRS 0.01
  • IDE 0.00
  • Stochastic Oscillator
  • CHRS 91.74
  • IDE 93.18

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: